From: Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis
ID | Immunosuppressive treatment at time of HEV infection | Cumulative dose of CYC before HEV infection | Cumulative dose of RTX before HEV infection | Daily prednisolone dose at HEV infection | Other potentially hepatotoxic co-medication | Length of immune-suppressant discontinuation | Flare and BVAS | GC increase |
---|---|---|---|---|---|---|---|---|
#1 | MTX 20 mg/week s.c., Mepolizumab 300 mg/month | 6 g | 0 g | 0 mg | Amlodipine | 4 months 4 weeks | No | No |
#2 | MTX 15 mg/week p.o | 0 g | 0 g | 2.5 mg | None | 10 weeks | Yes 4 | Yes 5 mg |
#3 | MMF 2 g/day | 2 g | 2 g | 5.0 mg | Trimethoprim/sulfamethoxazole | 4 days | Yes 10 | Yes 7.5 mg |
#4 | CYC 15 mg/kg i.v. pulse for remission induction | 2.25 g | 0 g | 12.5 mg | Ciprofloxacin | 4 months | No | No |
#5 | MTX 15 mg/week s.c | 0 g | 0 g | 5 mg | Cefuroxime | 4 weeks | Yes 4 | No |